Published in Blood on February 08, 2005
IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol (2008) 3.53
Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol (2009) 2.00
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res (2007) 2.00
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant (2009) 1.84
Current issues in chronic graft-versus-host disease. Blood (2014) 1.83
Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant (2008) 1.32
Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res (2007) 1.06
Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res (2011) 1.06
Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype. PLoS One (2012) 1.04
Extracorporeal Photochemotherapy as a Challenging Treatment for Cutaneous T-Cell Lymphoma, Acute and Chronic Graft-versus-Host Disease, Organ Rejection and T-Lymphocyte-Mediated Autoimmune Diseases. Transfus Med Hemother (2007) 0.91
Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease. PLoS One (2013) 0.88
Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol (2014) 0.85
Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica (2011) 0.83
Evaluation of prognostic factors among patients with chronic graft-versus-host disease. Haematologica (2012) 0.82
Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer. Front Immunol (2013) 0.82
Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review). Placenta (2011) 0.81
Wharton's Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals (Basel) (2015) 0.80
Does minor histocompatibility antigen HA-1 disparity affect the occurrence of graft-versus-host disease in tunisian recipients of hematopoietic stem cells? Clinics (Sao Paulo) (2010) 0.77
Acute graft-versus-host disease of the kidney in allogeneic rat bone marrow transplantation. PLoS One (2014) 0.76
Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease. Biol Blood Marrow Transplant (2009) 0.76
Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy. Epilepsy Behav Case Rep (2015) 0.75
Medication nonadherence to immunosuppressants after adult allogeneic haematopoietic stem cell transplantation: a multicentre cross-sectional study. Bone Marrow Transplant (2016) 0.75
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78
Regulatory T cells in the control of immune pathology. Nat Immunol (2001) 6.98
Regulatory T cells in transplantation tolerance. Nat Rev Immunol (2003) 6.42
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11
Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Chronic graft-versus-host disease. Biol Blood Marrow Transplant (2003) 5.36
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol (2001) 2.69
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2002) 2.40
Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 2.20
How I treat chronic graft-versus-host disease. Blood (2001) 2.20
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.15
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2005) 2.12
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant (1999) 1.96
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol (1976) 1.85
Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood (2004) 1.82
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood (2003) 1.79
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant (2003) 1.75
The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood (2003) 1.70
Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood (2004) 1.69
Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev (1992) 1.68
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica (2003) 1.50
Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet (2002) 1.49
Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant (1998) 1.47
Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol (1995) 1.46
Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol (1999) 1.45
Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood (2002) 1.41
Effects of exogenous interleukin-7 on human thymus function. Blood (2002) 1.38
Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood (2004) 1.38
High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun (1995) 1.36
Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood (2002) 1.34
Cutaneous graft-versus-host disease. Arch Dermatol (1998) 1.33
Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood (2003) 1.33
Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood (2003) 1.32
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood (2004) 1.30
Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation (2001) 1.25
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood (2004) 1.23
Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant (2003) 1.23
Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood (2004) 1.20
Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol (2001) 1.19
An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol (1985) 1.13
A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant (2002) 1.11
Transplantation tolerance induced by intranasal administration of HY peptides. Blood (2004) 1.11
Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood (2001) 1.08
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol (2002) 1.08
Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant (1996) 1.06
Chronic graft-versus-host disease. Bone Marrow Transplant (1990) 1.05
High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant (1997) 1.04
Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet (2003) 1.03
Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood (2001) 1.03
Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol (1995) 1.02
Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med (1992) 1.01
Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma (1995) 0.99
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood (1997) 0.99
Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant (2003) 0.98
Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation (2003) 0.97
Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2002) 0.96
Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol (2001) 0.96
Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol (2003) 0.95
Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation (1999) 0.95
Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol (2003) 0.95
Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1997) 0.94
Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood (1990) 0.93
Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol (1996) 0.92
Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant (2000) 0.92
IL-7 enhances the responsiveness of human T cells that develop in the bone marrow of athymic mice. J Immunol (2001) 0.91
Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation (2004) 0.90
Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft-versus-host disease by an enhanced expansion of regulatory CD8+ T cells. J Immunol (2000) 0.89
Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol (1996) 0.89
Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation (2002) 0.86
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant (1996) 0.86
Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease. Transplantation (2002) 0.86
Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation (2003) 0.84
Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. Bone Marrow Transplant (2002) 0.84
Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol (2003) 0.83
Chronic graft-versus-host disease: where do we go from here? Bone Marrow Transplant (2004) 0.81
Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model. Blood (2000) 0.80
The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. Bone Marrow Transplant (1998) 0.80
Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model. Bone Marrow Transplant (2003) 0.79
Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant (2001) 0.79
Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol (2003) 0.78